- Home
- EBMT vs IMUX Comparison
EBMT vs IMUX Comparison
Compare EBMT & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBMT | IMUX |
|---|---|---|
| Founded | 1922 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.7M | 155.8M |
| IPO Year | 2009 | 2013 |
Fundamental Metrics
Financial Performance| Metric | EBMT | IMUX |
|---|---|---|
| Price | $20.86 | $6.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $24.00 | ★ $43.09 |
| AVG Volume (30 Days) | 22.0K | ★ 417.3K |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | ★ 53.23 | 38.00 |
| EPS | ★ 0.98 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.89 | N/A |
| Revenue Next Year | $3.84 | N/A |
| P/E Ratio | $21.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.80 | $0.51 |
| 52 Week High | $24.66 | $17.43 |
Technical Indicators
Market Signals| Indicator | EBMT | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 37.19 | 28.28 |
| Support Level | $20.00 | $0.83 |
| Resistance Level | $22.84 | $8.60 |
| Average True Range (ATR) | 0.72 | 0.69 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 30.73 | 17.84 |
Price Performance
Historical ComparisonAbout EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.